Kyntra Bio Inc (NASDAQ:KYNB – Free Report) – Investment analysts at HC Wainwright decreased their Q3 2026 earnings per share estimates for shares of Kyntra Bio in a research note issued to investors on Friday, August 14th. HC Wainwright analyst M. Keller now expects that the company will earn ($4.31) per share for the quarter, down from their prior estimate of ($3.87). The consensus estimate for Kyntra Bio’s current full-year earnings is ($13.75) per share. HC Wainwright also issued estimates for Kyntra Bio’s Q4 2026 earnings at ($4.80) EPS, FY2026 earnings at ($2.33) EPS, FY2027 earnings at ($9.27) EPS and FY2028 earnings at ($9.21) EPS.
Several other equities analysts have also issued reports on the company. Weiss Ratings raised Kyntra Bio from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday. Oppenheimer began coverage on Kyntra Bio in a research report on Monday, July 6th. They issued an “outperform” rating and a $35.00 target price for the company. Finally, Rodman & Renshaw started coverage on Kyntra Bio in a research report on Tuesday, June 9th. They issued a “buy” rating and a $30.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $32.50.
Kyntra Bio Price Performance
Shares of KYNB opened at $6.81 on Tuesday. The company has a market capitalization of $27.58 million, a price-to-earnings ratio of 0.15 and a beta of 1.02. Kyntra Bio has a 1 year low of $6.32 and a 1 year high of $12.60. The business has a 50-day moving average of $7.09 and a 200-day moving average of $7.16.
Institutional Trading of Kyntra Bio
An institutional investor recently bought a new stake in Kyntra Bio stock. Renaissance Technologies LLC bought a new position in Kyntra Bio Inc (NASDAQ:KYNB – Free Report) in the first quarter, according to its most recent disclosure with the SEC. The firm bought 27,481 shares of the company’s stock, valued at approximately $186,000. Renaissance Technologies LLC owned about 0.68% of Kyntra Bio as of its most recent SEC filing. Institutional investors and hedge funds own 72.71% of the company’s stock.
About Kyntra Bio
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Featured Stories
- Five stocks we like better than Kyntra Bio
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Kyntra Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyntra Bio and related companies with MarketBeat.com's FREE daily email newsletter.
